Held by 6 specialist biotech funds
High Convergence**Signal Note: Rock Springs Capital initiates $17.8M NBIX position** Rock Springs' entry into NBIX likely reflects conviction in the company's late-stage pipeline, particularly valoctocogene roxaparvovec (ROCTAVIAN) for hemophilia A, which is approaching potential regulatory decision in 2024-2025, or confidence in near-term revenue inflection from existing commercialized products.
AI analyst context — unlock full analysis
**Signal Note: RTW Initiates $150.6M Position in NBIX** RTW's entry suggests confidence in NBIX's near-term catalysts, likely driven by upcoming clinical data or regulatory milestones for key pipeline assets (notably valoctocogene roxaparvovec in hemophilia A or oculocutaneous albinism programs). The $150.6M position size indicates conviction in near-term value realization rather than speculative accumulation, typical of RTW's event-driven approach.
+ 4 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial